Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

28.36 -0.34 (-1.17%)
Streaming Delayed Price Updated: 10:15 AM EDT, May 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 345,965
Open 28.69
Bid (Size) 28.32 (100)
Ask (Size) 28.39 (100)
Prev. Close 28.69
Today's Range 28.20 - 28.94
52wk Range 22.96 - 43.15
Shares Outstanding 99,581,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party ↗
This dark horse in the weight loss drug race is worth keeping on your watch list. 
Via The Motley Fool
News headline image
Eli Lilly Stock: Next Stop $2,000? ↗
The company is riding an incredible tailwind. 
Via The Motley Fool

Performance

YTD
-19.9%
-19.9%
1 Month
-20.2%
-20.2%
3 Month
-6.9%
-6.9%
6 Month
-25.8%
-25.8%
1 Year
+3.1%
+3.1%

More News

Read More
News headline image
Should Eli Lilly Investors Worry About Its Newest Rival -- From Within? ↗
Via The Motley Fool
Viking Therapeutics (NASDAQ:VKTX) Stock Holds Steady After Q1 2026 Earnings Miss on Higher Phase 3 Spending ↗
Via Chartmill
Topics Earnings
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
Via Investor Brand Network
InvestorNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation
Via Investor Brand Network
News headline image
Here's Exactly Why Wall Street Thinks Viking Therapeutics Stock Could Soar 207% Over the Next 12 Months ↗
Via The Motley Fool
News headline image
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
From BioMedWire
Via GlobeNewswire
News headline image
Eli Lilly Just Announced Fantastic News for Shareholders ↗
Via The Motley Fool
Topics Earnings
News headline image
Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge ↗
Via MarketBeat
News headline image
Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead? ↗
Via The Motley Fool
News headline image
This Obesity Stock Could More Than Double Over the Next 12 Months, According to Wall Street ↗
Via The Motley Fool
News headline image
Is This Tech Giant the Next Potential Winner in the GLP-1 Weight Loss Boom? ↗
Via The Motley Fool
News headline image
The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
From Equity Insider
Via GlobeNewswire
News headline image
Better Long-Term Buy: Eli Lilly or Viking Therapeutics? ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Is Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026? ↗
Via The Motley Fool
News headline image
Better Healthcare Stock to Own in a Recession: Defensive or Growth? ↗
Via The Motley Fool
Topics Economy Energy
News headline image
Where Will Viking Therapeutics Stock Be in 10 Years? ↗
Via The Motley Fool
News headline image
The Great Metabolic Land Grab: Why Viking and Structure Have Become Big Pharma’s 'Irresistible' Targets
Via MarketMinute
Topics Intellectual Property
News headline image
Eli Lilly Secures Landmark FDA Approval for Oral Weight-Loss Pill, Sending Shares Soaring
Via MarketMinute
Topics Economy
News headline image
2 Healthcare Stocks Wall Street Analysts Say Could Rally 60% or More ↗
Via The Motley Fool
News headline image
1 Reason This Biotech Stock Could Triple Before Year-End ↗
Via The Motley Fool
News headline image
Why Viking Therapeutics Stock Could Take Off Later This Year ↗
Via The Motley Fool
News headline image
Goldman Sachs Bullish Forecast: 15% Increase in 2026 U.S. M&A Activity
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Small-Cap Resilience: Russell 2000 Surges 3% as Geopolitical Tensions Ease and ‘Risk-On’ Appetite Returns
Via MarketMinute
Topics ETFs Economy Stocks

Frequently Asked Questions

Is Viking Therapeutics, Inc. - Common Stock publicly traded?
Yes, Viking Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Viking Therapeutics, Inc. - Common Stock trade on?
Viking Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Viking Therapeutics, Inc. - Common Stock?
The ticker symbol for Viking Therapeutics, Inc. - Common Stock is VKTX on the Nasdaq Stock Market
What is the current price of Viking Therapeutics, Inc. - Common Stock?
The current price of Viking Therapeutics, Inc. - Common Stock is 28.36
When was Viking Therapeutics, Inc. - Common Stock last traded?
The last trade of Viking Therapeutics, Inc. - Common Stock was at 05/19/26 10:15 AM ET
What is the market capitalization of Viking Therapeutics, Inc. - Common Stock?
The market capitalization of Viking Therapeutics, Inc. - Common Stock is 2.82B
How many shares of Viking Therapeutics, Inc. - Common Stock are outstanding?
Viking Therapeutics, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.